LEADER 5: Prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: Baseline global data from the LEADER trial

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Masmiquel, L ^a   Leiter, L A ^b   Vidal, J ^c   Bain, S ^d   Petrie, J ^e   Franek, E ^f   Raz, I ^g   Comlekci, A ^h   Jacob, S ⁱ   Gaal, L ^j   Baeres, F M M ^k   Marso, S P ^l   Eriksson, M ^m  

^a UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF BARCELONA   (Spain)

^d SWANSEA UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^h Department of Internal Medicine   (Turkey)

ⁱ Kardio Metabolischen Instituts   (Germany)

^j ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^k NOVO NORDISK A S   (Denmark)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^m KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

more..

Author keywords

Cardiometabolic; Cardiovascular; LEADER; Liraglutide; Obesity; Overweight; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIRAGLUTIDE; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; ANTIDIABETIC AGENT;

ABDOMINAL OBESITY; ADULT; AGE; AGED; AMERICAN; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; DRUG EFFECT; DRUG SAFETY; DRUG USE; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; METABOLIC SYNDROME X; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WAIST CIRCUMFERENCE;

EID: 84957894002     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0341-5     Document Type: Article

References (47)

1. Bastien M, Poirier P, Lemieux I, Despres JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56:369-81.
2. Bhan V, Yan RT, Leiter LA, Fitchett DH, Langer A, Lonn E, et al. Guidelines oriented approach in lipid lowering (GOALL) registry and vascular protection (VP) registry investigators. Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. Am J Cardiol. 2010;106:1270-6.
3. Goyal A, Nimmakayala KR, Zonszein J. Is there a paradox in obesity? Cardiol Rev. 2014;22:163-70.
4. Leenders M, Verdijk LB, van der Hoeven L, Adam JJ, van Kranenburg J, Nilwik R, et al. Patients with type 2 diabetes show a greater decline in muscle mass, muscle strength, and functional capacity with aging. J Am Med Dir Assoc. 2013;14:585-92.
5. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53:1925-32.
6. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145-54.
7. Marso SP, Poulter NR, Nissen SE, Nauck MA, Zinman B, Daniels GH, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823-30.
8. Sumner AE. The relationship of body fat to metabolic disease: influence of sex and ethnicity. Gend Med. 2008;5:361-71.
9. Goh LG, Dhaliwal SS, Welborn TA, Lee AH, Della PR. Anthropometric measurements of general and central obesity and the prediction of cardiovascular disease risk in women: a cross-sectional study. BMJ Open. 2014;4:e004138.
10. Ntuk UE, Gill JM, Mackay DF, Sattar N, Pell JP. Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes Care. 2014;37:2500-7.
11. Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/American heart Association task force on practice guidelines and the obesity society. Circulation. 2014;129:S102-38.
12. Expert Panel on Detection. Evaluation and treatment of high blood cholesterol in adults. executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-97.
13. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
14. Tillin T, Sattar N, Godsland IF, Hughes AD, Chaturvedi N, Forouhi NG. Ethnicity-specific obesity cut-points in the development of Type 2 diabetes-a prospective study including three ethnic groups in the United Kingdom. Diabet Med. 2015;32:226-34.
15. American Diabetes Association. Standards of medical care in diabetes-2014. Diabetes Care. 2014;37:S14-80.
16. Baxi S, Lakin J, Lyles CR, Berkowitz S, Horton C, Sarkar U. Points for improvement: performance measurement for glycemic control in diabetes patients in a safety-net population. Jt Comm J Qual Patient Saf. 2013;39:109-13.
17. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014;384:766-81.
18. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med. 2014;160:517-25.
19. Albu JB, Lu J, Mooradian AD, Krone RJ, Nesto RW, Porter MH, et al. Relationships of obesity and fat distribution with atherothrombotic risk factors: baseline results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Obesity (Silver Spring). 2010;18:1046-54.
20. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26.
21. Vázquez LA, Rodríguez Á, Salvador J, Ascaso JF, Petto H, Reviriego J. Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage. BMC Cardiovasc Disord. 2014;14:153.
22. McEwen LN, Karter AJ, Waitzfelder BE, Crosson JC, Marrero DG, Mangione CM, et al. Predictors of mortality over 8 years in type 2 diabetic patients: translating research into action for diabetes (TRIAD). Diabetes Care. 2012;35:1301-9.
23. Logue J, Walker JJ, Colhoun HM, Leese GP, Lindsay RS, McKnight JA, et al. Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia. 2011;54:3003-6.
24. Collier A, Ghosh S, Hair M, Waugh N. Gender differences and patterns of cardiovascular risk factors in Type 1 and Type 2 diabetes: a population-based analysis from a Scottish region. Diabet Med. 2015;32:42-6.
25. Molenaar EA, Hwang SJ, Vasan RS, Grobbee DE, Meigs JB, D'Agostino RB Sr, et al. Burden and rates of treatment and control of cardiovascular disease risk factors in obesity: the Framingham Heart Study. Diabetes Care. 2008;31:1367-72.
26. Swinburn BA, Sacks G, Hall KD, McPherson K, Finegood DT, Moodie ML, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378:804-14.
27. Chopra I, Kamal KM, Candrilli SD, Kanyongo G. Association between obesity and therapeutic goal attainment in patients with concomitant hypertension and dyslipidemia. Postgrad Med. 2014;126:66-77.
28. Li P, Chen K, Nie Y, Guo LL, Wang HB, Wang SS, et al. Association of obesity with glucose, blood pressure, and lipid goals attainment in patients with concomitant diabetes and hypertension. Curr Med Res Opin. 2015;31:1623-31.
29. Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH. Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J. 2006;82:280-4.
30. Rückert IM, Maier W, Mielck A, Schipf S, Völzke H, Kluttig A, et al. Personal attributes that influence the adequate management of hypertension and dyslipidemia in patients with type 2 diabetes. Results from the DIAB-CORE cooperation. Cardiovasc Diabetol. 2012;11:120.
31. Jones NR, Fischbacher CM, Guthrie B, Leese G, Lindsay RS, McKnight JA, et al. Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008. Diabet Med. 2014;31:640-6.
32. Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the trial evaluating cardiovascular outcomes with Sitagliptin (TECOS). Diabetes Obes Metab. 2015;17:395-402.
33. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;2014(63):2889-934.
34. American Diabetes Association. Cardiovascular disease and risk management. Sec. 8. In standards of medical care in diabetes 2015. Diabetes Care. 2015;38:S49-57.
35. Ludman A, Venugopal V, Yellon DM, Hausenloy DJ. Statins and cardioprotection-more than just lipid lowering? Pharmacol Ther. 2009;122:30-43.
36. Guenette L, Breton MC, Hamdi H, Gregoire JP, Moisan J. Important treatment gaps in vascular protection for the elderly after type 2 diabetes therapy initiation. Can J Cardiol. 2013;29:1593-8.
37. Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, et al. Risk factor control for coronary artery disease secondary prevention in large randomized trials. J Am Coll Cardiol. 2013;61:1607-15.
38. Niswender K, Pi-Sunyer X, Buse J, Jensen KH, Toft AD, Russell-Jones D, et al. Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab. 2013;15:42-54.
39. The Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9784):1085-95.
40. Weeke P, Andersson C, Fosbøl EL, Brendorp B, Køber L, Sharma AM, et al. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus-an analysis from the SCOUT lead-in period. BMC Endocr Disord. 2010;10:3.
41. Caterson ID, Finer N, Coutinho W, van Gaal LF, Maggioni AP, Torp-Pedersen C, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the sibutramine cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012;14:523-30.
42. Wormser D, Wood AM, Di Angelantonio E, Thompson SG, Danesh J. Emerging risk factors collaboration. Metabolic mediators of body-mass index and cardiovascular risk. Lancet. 2014;383:2042-3.
43. Paul SK, Klein K, Maggs D, Best JH. The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study. Cardiovasc Diabetol. 2015;14:10.
44. Blonde L, Pencek R, MacConell L. Association among weight change, glycemic control, and markers of cardiovascular risk with exenatide once weekly: a pooled analysis of patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:12.
45. Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:36.
46. Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11-22.
47. Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687-99.